[1]付燕,张月玲,王丽英,等.湿性年龄相关性黄斑变性患者抗VEGF治疗无效的因素分析和视功能预后[J].眼科新进展,2021,41(3):254-258.[doi:10.13389/j.cnki.rao.2021.0053]
　FU Yan,ZHANG Yueling,WANG Liying,et al.Factors and outcomes associated with failure to anti-VEGF treatment in patients with wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2021,41(3):254-258.[doi:10.13389/j.cnki.rao.2021.0053]
点击复制

湿性年龄相关性黄斑变性患者抗VEGF治疗无效的因素分析和视功能预后/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
41卷
期数:
2021年3期
页码:
254-258
栏目:
应用研究
出版日期:
2021-03-05

文章信息/Info

Title:
Factors and outcomes associated with failure to anti-VEGF treatment in patients with wet age-related macular degeneration
作者:
付燕; 张月玲; 王丽英; 李丽英; 陈强; 顾朝辉
071000　河北省保定市，保定市第一中心医院眼二科
Author(s):
FU Yan; ZHANG Yueling; WANG Liying; LI Liying; CHEN Qiang; GU Zhaohui
Department of Ophthalmology,Baoding No.1 Central Hospital,Baoding 071000,Hebei Province,China
关键词:
年龄相关性黄斑变性; 脉络膜新生血管; 抗VEGF治疗
Keywords:
age-related macular degeneration;  choroidal neovascularization;  anti-VEGF treatment
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2021.0053
文献标志码:
A
摘要:
目的　探讨湿性年龄相关性黄斑变性（wAMD）患者玻璃体内注射抗血管内皮生长因子（VEGF）治疗无效的影响因素和视功能预后。方法　回顾性分析97例（97眼）wAMD患者的临床资料，所有患者均进行连续3个月、玻璃体内每个月注射1次抗VEGF治疗。观察并记录患者治疗后最佳矫正视力（BCVA）、黄斑中心凹视网膜厚度（CMT）。根据患者连续3次抗VEGF治疗后1个月的效果分为无效组和有效组。单因素分析筛选wAMD患者抗VEGF治疗无效的危险因素，多因素Logistic回归分析确定治疗无效的独立危险因素；观察治疗无效患者的后续治疗和视功能预后情况。结果　抗VEGF治疗后1个月、2个月、3个月和末次随访时wAMD患者BCVA较治疗前均有明显改善，差异均有统计学意义（均为P<0.05），CMT较治疗前均有减低，差异均有统计学意义（均为P<0.05）。连续3次抗VEGF治疗后1个月，wAMD患者无效21眼（无效组），有效76眼（有效组）。多因素 Logistic 回归分析结果显示：年龄（OR=2.132，95%CI=2.314~44.342，P=0.011）、基线BCVA（OR=8.361，95%CI=7.239~32.764，P=0.009）是抗VEGF治疗无效的独立影响因素。无效组12例（57.1%）更换抗VEGF药物治疗，33.3%患者更换抗VEGF药物后视力改善，5例（23.8%）联合PDT治疗后视力与单纯抗VEGF治疗相比，差异无统计学意义（P>0.05）。结论　高龄及基线视力差是抗VEGF治疗无效的独立影响因素，部分治疗无效患者更换治疗药物后可改善视力预后。
Abstract:
Objective　To identify factors associated with ineffectiveness to anti-vascular endothelial growth factor (VEGF) treatment in patients with wet age-related macular degeneration (wAMD) and outcomes of patients with failure to treatment.Methods　This retrospective study included 97 patients who received monthly anti-VEGF treatment for 3 months for wAMD. Best corrected visual acuity (BCVA) and central macular thickness (CMT) were evaluated throughout the treatment period. Patients were divided into ineffective group and effective group depending on the effectiveness 1 month after treatment with three loading injections of anti-VEGF agent．The risk factors of ineffective anti-VEGF treatment in WAMD patients by univariate analysis, and the independent risk factors associated with treatment failure were determined with multivariate stepwise logistic regression analysis. Finally, we analyzed the follow-up treatment and outcomes of patients with failure to treatment.Results　The mean logMAR BCVA significantly improved from baseline to follow-up (all P<0.05), and there were significant reductions of CMT compared with the baseline (all P<0.05) 1 month, 2 months, 3 months and the last follow up after anti-VEGF treatment. One month after three loading injections of anti-VEGF agent, 21 patients were classified as ineffective group and 76 patients were classified as effective group. In multivariate analysis, age (OR=2.132，95%CI=2.314-44.342，P=0.011) and baseline BCVA (OR=8.361，95%CI=7.239-32.764，P=0.009) were independent predictors for ineffectiveness. In 12 eyes (57.1%) of the ineffective group received a change of the anti-VEGF agent, and only 33.3% eyes showed an increase of visual acuity thereafter; 5 eyes (23.8%) of ineffective group were subsequently treated with photodynamic therapy (PDT) in combination with anti-VEGF injections, but visual acuity was not improved compared with patients treated with only anti-VEGF injections.Conclusion　Independent predictors for ineffectiveness were age and lower baseline visual acuity. Change of the anti-VEGF agent was effective for part of eyes of non-responders.

参考文献/References:

［1］　van ASTEN F,ROVERS M M,LECHANTEUR Y T,SMAILHODZIC D,MUETHER P S,CHEN J,et al.Predicting non-response to ranibizumab in patients with neovascular age-related macular degeneration［J］.Ophthalmic Epidemiol，2014，21(6):347-355.
［2］　SUZUKI M,NAGAI N,IZUMI-NAGAI K,SHINODA H,KOTO T,UCHIDA A,et al.Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration［J］.Br J Ophthalmol,2014,98(9):1186-1191.
［3］　KREBS I,GLITTENBERG C,ANSARI-SHAHREZAEI S,HAGEN S,STEINER I,BINDER S.Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration［J］.Br J Ophthalmol,2013,97(11):1443-1446.
［4］　TARAKCIOGLU H N,OZKAYA A,KEMER B,TASKAPILI M.Multimodal imaging based biomarkers predictive of early and late response to anti-VEGFs during the first year of treatment for neovascular age-related macular degeneration［J］.J Fr Ophthalmol,2019,42(1):22-31.
［5］　IACONO P,BATTAGLIA PARODI M,BANDELLO F.Non-responders to intravitreal ranibizumab in subfoveal choroidal neovascularization secondary to age-related macular degeneration［J］.Ophthalmic Res,2017,57(1):42-47.
［6］　FULCHER C,HAZEL C A,PACEY I,ALI H,GHANCHI F D.Predicting visual outcomes in patients treated with aflibercept for neovascular age-related macular degeneration:Data from a real-world clinical setting［J］.Eur J Ophthalmol,2020,30(3):543-549.
［7］　STOLLER G L,KOKAME G T,DREYER R F,SHAPIRO H,TUOMI L L.Patterns of early and delayed visual response to ranibizumab treatment for neovascular age-related macular degeneration［J］.JAMA Ophthalmol,2016,134(5):545-553.
［8］　MENGHINI M,KURZ-LEVIN M M,AMSTUTZ C,MICHELS S,WINDISCH R,BARTHELMES D,et al.Response to ranibizumab therapy in neovascular AMD-an evaluation of good and bad responders［J］.Klin Monbl Augenheilkd,2010,227(4):244-248.
［9］　VELUSWAMY B,LEE A,MIRZA R G,GILL M K.Correlation of baseline visual acuity with outcomes of treatment with anti-VEGF in neovascular age-related macular degeneration［J］.Clin Ophthalmol,2020,14:1565-1572.
［10］　HARA C,WAKABAYASHI T,TOYAMA H,FUKUSHIMA Y,SAYANAGI K,SATO S,et al.Characteristics of patients with neovascular age-related macular degeneration who are non-responders to intravitreal aflibercept［J］.Br J Ophthalmol,2018,bjophthalmol-2018-312275.
［11］　de OLIVEIRA DIAS J,RODRIGUESE B,MAIA M,MAGALHAES O,PENHA F M,FARAH M E.Cytokines in neovascular age-related macular degeneration:fundamentals of targeted combination therapy［J］.Br J Ophthalmol,2011,95(12):1631-1637.
［12］　WANG Y,WANG V M,CHAN C C.The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment［J］.Eye,2011,25(2):127-139.
［13］　FRANCIS P J.The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration:the Lucentis Genotype Study (an American Ophthalmological Society thesis) ［J］.Trans Am Ophthalmol Soc,2011,109:115-156.
［14］　LANZETTA P,CRUESS A F,COHEN S Y,SLAKTER J S,KATZ T,SOWADE O,et al.Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy:post hoc analysis of the VIEW studies［J］.Acta Ophthalmol,2018,96(8):e911-e918.
［15］　YING G S,HUANG J,MAGUIRE M G,JAFFE G J,GRUNWALD J E,TOTH C,et al.Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration［J］.Ophthalmology,2013,120(1):122-129.
［16］　TUFAIL A,MARGARON P,GUERIN T,LARSEN M.Visual benefit versus visual gain:what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA［J］.Br J Ophthalmol,2020,104(5):672-677.
［17］　BLOCH S B,LA COUR M,SANDER B,HANSEN L K,FUCHS J,LUND-ANDERSEN H,et al.Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment［J］.Acta Ophthalmol,2013,91(1):42-47.

相似文献/References:

[1]范姜砾 王雨生 张鹏.湿性年龄相关性黄斑变性患者血浆中相关抗氧化酶水平测定[J].眼科新进展,2012,32(5):000.
[2]王毅 李罗翔 李娟 曾庆华.ApoE基因缺失小鼠视网膜及Bruch膜组织形态观察[J].眼科新进展,2013,33(1):000.
[3]徐新荣 仲路 黄冰林 魏源华 周欣 王玲 王富强.年龄相关性黄斑变性血浆蛋白质组学初步研究[J].眼科新进展,2013,33(2):000.
[4]王毅 李罗翔 李进辉 李娟 曾庆华.血脂异常ApoE基因缺失小鼠视网膜色素上皮细胞胞浆内黑色素和脂褐素的改变[J].眼科新进展,2013,33(7):000.
[5]许瑶 曾骏文.近视眼药物治疗研究进展[J].眼科新进展,2013,33(7):000.
[6]许琴 黄亮 林素香 郑水华 肖煜晨 王雅丽.激光诱导小鼠脉络膜新生血管中膜攻击物与血管生长因子的表达[J].眼科新进展,2013,33(8):000.
[7]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[8]詹文捷 梁丽娜 唐由之.骨髓来源细胞参与脉络膜新生血管形成的研究进展[J].眼科新进展,2012,32(1):000.
[9]陈丽娟 苗林.重组人血管内皮抑素对脉络膜新生血管的抑制作用[J].眼科新进展,2012,32(10):000.
[10]金昱 石安娜 刘维锋 石浔 王永波.频域OCT在光动力疗法治疗病理性近视脉络膜新生血管中的应用[J].眼科新进展,2012,32(10):000.
[11]党亚龙 陈彬川 穆雅林 赵满丽 朱豫.i-MP对产生2型脉络膜新生血管的年龄相关性黄斑变性患者视力及黄斑厚度的影响[J].眼科新进展,2013,33(2):000.
[12]栾兰 姚勇.湿性年龄相关性黄斑变性的治疗进展[J].眼科新进展,2013,33(4):000.
[13]胡艳红 祁明信 郭娜 陈胜 柯发杰.渗出型年龄相关性黄斑变性患者外周血CCR3的表达[J].眼科新进展,2013,33(11):000.
[14]魏菁,黄厚斌. 吲哚青绿介导的光栓塞治疗黄斑中心凹下脉络膜新生血管[J].眼科新进展,2014,34(9):842.[doi:10.13389/j.cnki.rao.2014.0232]
[15]于靖,刘晴雨,吴岩.阿司匹林是年龄相关性黄斑变性的危险因素[J].眼科新进展,2014,34(10):901.[doi:10.13389/j.cnki.rao.2014.0249]
[16]朱磊,田晓燕,刘涛.玻璃体内注射康柏西普治疗湿性年龄相关性黄斑变性的临床观察[J].眼科新进展,2017,37(5):473.[doi:10.13389/j.cnki.rao.2017.0120]
　ZHU Lei,TIAN Xiao-Yan,LIU Tao.Intravitreal injection of conbercept for wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2017,37(3):473.[doi:10.13389/j.cnki.rao.2017.0120]
[17]卢悦,蔡玲,朱晨,等.人参皂苷RG3对脉络膜新生血管的抑制作用[J].眼科新进展,2017,37(10):922.[doi:10.13389/j.cnki.rao.2017.0234]
　LU Yue,CAI Ling,ZHU Chen,et al.Inhibitory effect of ginsenoside RG3 on choroidal neovascularization[J].Recent Advances in Ophthalmology,2017,37(3):922.[doi:10.13389/j.cnki.rao.2017.0234]
[18]邵毅,周琼.年龄相关性黄斑变性诊断与治疗规范——2018年英国专家共识解读[J].眼科新进展,2019,39(11):1001.[doi:10.13389/j.cnki.rao.2019.0229]
　SHAO Yi,ZHOU Qiong.Diagnosis and treatment of age-related macular degeneration:An interpretation of British National Institute for Health and Care Excellence (NICE) in 2018[J].Recent Advances in Ophthalmology,2019,39(3):1001.[doi:10.13389/j.cnki.rao.2019.0229]
[19]胡伟男,蔡文婷,邹爱琪,等.精氨酸-甘氨酸-天冬氨酸修饰的星型高分子负载雷珠单抗对脉络膜新生血管靶向治疗作用[J].眼科新进展,2021,41(2):130.[doi:10.13389/j.cnki.rao.2021.0027]
　HU Weinan,CAI Wenting,ZOU Aiqi,et al.Targeted therapy effect of arginine-glycine-aspartate modified star polymer loaded ranibizumab on choroidal neovascularization[J].Recent Advances in Ophthalmology,2021,41(3):130.[doi:10.13389/j.cnki.rao.2021.0027]
[20]胡梦燕,邵毅,裴重刚.年龄相关性黄斑变性患者色素上皮形态与最佳矫正视力的关系研究进展[J].眼科新进展,2021,41(8):797.[doi:10.13389/j.cnki.rao.2021.0167]
　HU Mengyan,SHAO Yi,PEI Chonggang.Research progress on the relationship between pigment epithelium morphology and best corrected visual acuity in patients with age-related macular degeneration[J].Recent Advances in Ophthalmology,2021,41(3):797.[doi:10.13389/j.cnki.rao.2021.0167]

备注/Memo

备注/Memo:
N/A
更新日期/Last Update: 2021-03-05